TP53 and neoplasm: Low-grade gliomas (LGGs) and GBM have shown IDH 1/2 mutations may be due to specific effects of it on tumor-associated immune response with genetic abnormalities in tumor protein 53 (TP53) gene [15]-encoding p53 protein, which modulates cell cycle progression and apoptosis, and functions as a tumor suppressor [16].